<DOC>
	<DOCNO>NCT00736931</DOCNO>
	<brief_summary>The primary objective study evaluate neurocognitive effect brivaracetam</brief_summary>
	<brief_title>Clinical Study Healthy Volunteers Investigate Neurocognitive Effects New Antiepileptic Drug : Brivaracetam</brief_title>
	<detailed_description />
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Healthy male female volunteer age 18 50 year inclusive Body Mass Index ( BMI ) 18.0 30.0 kg/m² inclusive Good physical mental health status Blood pressure heart rate within normal range Electrocardiogram laboratory test without clinically significant abnormality IQ ≤ 80 determined Test nonverbal intelligence Center Epidemiological Studies Depression ( CESD Scale ≥16 , Known allergy/intolerance pyrrolidinone derivative Abnormalities EEG recording Pregnant , lactate woman History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrinological , neurological , psychiatric disorder Use hepatic enzymeinducing drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Brivaracetam</keyword>
	<keyword>Cognitive neurophysiological test ( CNT )</keyword>
	<keyword>Neuropsychological assessment</keyword>
</DOC>